Atrial fibrillation screening remains debated, with experts disagreeing on whether current evidence justifies implementation or if randomized trials are needed to avoid overdiagnosis.
Should we screen for atrial fibrillation?
This editorial debates the readiness for a national atrial fibrillation screening program, contrasting the sufficiency of current evidence against the risk of overdiagnosis and the need for randomized trials.
Absolute Event Rate: 0% vs 0%
Current evidence is sufficient to justify a national screening programme, argues Mark Lown, but Patrick Moran thinks there are too many unanswered questions and evidence from randomised trials is needed to avoid overdiagnosis
Lown et al. (Wed,) reported a other. Atrial fibrillation screening remains debated, with experts disagreeing on whether current evidence justifies implementation or if randomized trials are needed to avoid overdiagnosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: